O. Goldblum

Changes in C‐reactive protein in patients with moderate‐to‐severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy

B. Strober, Y. Poulin, D. Williams, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH

Y. Poulin, R. Langley, R. Langley, 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

Sleep quality and other patient‐reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open‐label Phase IIIB trial

B. Strober, K. Duffin, M. Okun, 2012, The British journal of dermatology.

Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti‐tumour necrosis factor agents: subanalysis of BELIEVE

S. Chimenti, J. Ortonne, K. Reich, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Sleep quality and other patient‐reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open‐label Phase IIIB trial

K. Duffin, M. Okun, P. Mulani, 2012, The British journal of dermatology.